| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 01/16/2013 | CN102190612B Endophytic fungus diterpene alkaloid compound of natural seaweed as well as preparation method and application thereof |
| 01/16/2013 | CN102160874B Compound Chinese herbal medicine preparation for treating black mouth disease of sea urchin |
| 01/16/2013 | CN102133400B Method for removing split agent in vaccine preparation process |
| 01/16/2013 | CN102133399B Novel process for preparing influenza virus split vaccine |
| 01/16/2013 | CN102133201B Faropenem sodium freeze-dried powder injection |
| 01/16/2013 | CN102106852B Medicinal use of 2'2-bithiazole non-nucleoside compounds serving as hepatitis C virus inhibitor |
| 01/16/2013 | CN102086447B Duck virus hepatitis strains and inactivated vaccine |
| 01/16/2013 | CN102058817B Tibetan medicinal preparation for treating liver diseases |
| 01/16/2013 | CN101869633B Enteric-coated medicament combination containing epigallocatechin gallate |
| 01/16/2013 | CN101820872B Use of ricinoleic acid monoglyceride in antimicrobial agent and method for improving antimicrobial agent |
| 01/16/2013 | CN101677976B Use of activator of AMP-activated protein kinase in preparing medicine for inhibiting HIV replication |
| 01/16/2013 | CN101632627B Solution for ungual and peri-ungual application |
| 01/16/2013 | CN101610772B Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination |
| 01/16/2013 | CN101456905B Bacteria 5 type secretory protein and construction method and application thereof |
| 01/16/2013 | CN101454011B Tri and tetra-oligo-saccharides suitable as agglutination agents for enteric pathogens |
| 01/16/2013 | CN101405032B Anti-infective solution comprising a compound of pyrido(3,2,1-ij)-benzoxadiazine type |
| 01/16/2013 | CN101401935B Astragalus polysaccharide adjuvant and uses in type I riemerella anatipestifer inactivated vaccine |
| 01/16/2013 | CN101336958B Use of alkaloids extracted from sophora flavescens in preparing medicine for treating diseased induced by mycoplasma, chlamydia and fungus |
| 01/16/2013 | CN101128455B Heterocyclylamide-substituted imidazoles |
| 01/15/2013 | US8354408 N-containing heterocyclic compounds |
| 01/15/2013 | US8354115 Binding proteins; vaccines; increased cytokine and antibody production |
| 01/15/2013 | CA2693997C Viral polymerase inhibitors |
| 01/15/2013 | CA2650577C Use of 12-imidazolyl-1-dodecanol or its pharmaceutically acceptable salts for producing a pharmaceutical preparation |
| 01/15/2013 | CA2627790C Compositions useful for prevention and treatment of common cold and influenza-like symptoms |
| 01/15/2013 | CA2565431C Antibiotic compound produced by fermentation with streptomyces sp. |
| 01/15/2013 | CA2560253C Prodrugs of piperazine and substituted piperidine antiviral agents |
| 01/15/2013 | CA2466156C Ehrlichia disulfide bond formation proteins and uses thereof |
| 01/15/2013 | CA2461710C Incapacitated whole-cell immunogenic bacterial compositions |
| 01/15/2013 | CA2460269C Alphavirus replicon vector systems |
| 01/15/2013 | CA2451864C Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
| 01/15/2013 | CA2443323C Nucleic acid vaccines for prevention of flavivirus infection |
| 01/15/2013 | CA2346131C Method for improving the pharmacokinetics of tipranavir |
| 01/15/2013 | CA2323011C Method for the development of an hiv vaccine |
| 01/10/2013 | WO2013006842A2 Immunogenic compositions and uses thereof |
| 01/10/2013 | WO2013006738A1 Compounds for the treatment of hiv |
| 01/10/2013 | WO2013005698A1 Biological inorganic compound complex having reduced oxygen and high reducing ability |
| 01/10/2013 | WO2013005042A2 Anti-viral therapy |
| 01/10/2013 | WO2013004818A1 Darunavir combination formulations |
| 01/10/2013 | WO2013004816A1 Darunavir formulations |
| 01/10/2013 | WO2013004669A1 Multivalent oligosaccharides |
| 01/10/2013 | WO2013004185A1 Broadly cross-reactive hiv-1-specific antibodies for prevention and treatment of hiv |
| 01/10/2013 | WO2013004171A1 Use of c15-substituted andrographolide derivatives in preparation of anti-hepatitis b virus medicament |
| 01/10/2013 | WO2013004148A1 Method for preparation of 3-butoxy-2-pyrazineformamide and use thereof |
| 01/10/2013 | WO2013004145A1 Composition of chinese herbal compound or extract and use thereof |
| 01/10/2013 | WO2013004141A1 3-alkoxy-substituted-2-pyrazinyl formamide compound and use thereof |
| 01/10/2013 | WO2013004116A1 C-3 substituted-9-deoxidized-9a-aza-9a-erythromycin a derivative |
| 01/10/2013 | WO2013004092A1 3-oxo-3, 4-dihydro-2-pyrazineformamide derivatives, pharmaceutical compositions, preparation methods and uses thereof |
| 01/10/2013 | WO2013004032A1 Composition for treating chicken intestine toxicity syndrome and preparation method thereof |
| 01/10/2013 | WO2013004020A1 Pseudomonas aeruginosa (pa-msha) strain igy and preparation method and use thereof |
| 01/10/2013 | WO2012151474A3 Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria |
| 01/10/2013 | WO2012144754A3 Composition containing a galla rhois extract having virus inhibitory effects or a compound isolated therefrom as an active ingredient, and uses thereof |
| 01/10/2013 | WO2012141540A3 Novel isolated lactobacillus fermentum strain having viral infection inhibitory activity |
| 01/10/2013 | WO2012138806A3 Olive mill waste fractions, their preparation and uses |
| 01/10/2013 | WO2012134188A3 Novel oxazolidinone derivative and medical composition containing same |
| 01/10/2013 | WO2012106722A3 Treatment of bacterial infections |
| 01/10/2013 | WO2012097223A3 Oligosaccharide conjugates for targeting bacteria and uses related thereto |
| 01/10/2013 | WO2012092484A3 Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
| 01/10/2013 | WO2010055187A3 Use of rnase p as antiviral agent |
| 01/10/2013 | US20130012595 High alcohol content foaming compositions with silicone-based surfactants |
| 01/10/2013 | US20130012583 Vinyl substituted fatty acids |
| 01/10/2013 | US20130012573 Methods for intracellular delivery of nucleic acids |
| 01/10/2013 | US20130012567 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/10/2013 | US20130012558 Use of Fungicides for the Treatment of Fish Mycoses |
| 01/10/2013 | US20130012554 Oxazolidinone derivatives containing new bicyclic group, having antibacterial activity, and method for treating pathogenic bacterial infections using the same |
| 01/10/2013 | US20130012540 Hepatitis C Virus Inhibitors |
| 01/10/2013 | US20130012537 3,8-diaminotetrahydroquinoline derivative |
| 01/10/2013 | US20130012527 Preq1 riboswitches and methods and compositions for use of and with preq1 riboswitches |
| 01/10/2013 | US20130012506 Anti-infective pyrido (1,2-a) pyrimidines |
| 01/10/2013 | US20130012504 Bi-functional quinoline analogs |
| 01/10/2013 | US20130012502 Pharmaceutical or Veterinary Antiviral Compositions |
| 01/10/2013 | US20130012486 Combination steroid and glucocorticoid receptor antagonist therapy |
| 01/10/2013 | US20130012481 Crystalline forms of tigecycline hydrochloride |
| 01/10/2013 | US20130012480 Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same |
| 01/10/2013 | US20130012479 Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/10/2013 | US20130012472 Composition and methods of inhibiting gastrointestinal pathogen infection |
| 01/10/2013 | US20130012471 Means and methods for producing artificial capsular polysaccharides of neisseria meningitidis |
| 01/10/2013 | US20130012470 Antiviral compositions and methods of their use |
| 01/10/2013 | US20130012468 Chemical compounds |
| 01/10/2013 | US20130012466 Colchicine neoglycosides and methods for their synthesis and use |
| 01/10/2013 | US20130012444 Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/10/2013 | US20130012430 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| 01/10/2013 | US20130012429 Anti-viral therapy |
| 01/10/2013 | US20130011903 Thymidine Kinase Mutants and Fusion Proteins Having Thymidine Kinase and Guanylate Kinase Activities |
| 01/10/2013 | US20130011498 Method of using beta-hydroxy-beta-methylbutyrate for reducing tumor growth rate |
| 01/10/2013 | US20130011464 Drug carrier and drug carrier kit for inhibiting fibrosis |
| 01/10/2013 | US20130011457 Antimicrobial polymers and methods of manufacture thereof |
| 01/10/2013 | US20130011453 Buffered microencapsulated compositions and methods |
| 01/10/2013 | US20130011452 Topical foam composition |
| 01/10/2013 | US20130011437 Immune compositions for treating H. pylori infection |
| 01/10/2013 | US20130011435 Composition for treating hbv infection |
| 01/10/2013 | US20130011434 Adjuvant diluents for live vaccines for pig diseases |
| 01/10/2013 | US20130011433 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4 |
| 01/10/2013 | US20130011432 Disrupted adenovirus-based vaccine against drugs of abuse |
| 01/10/2013 | US20130011429 Immunogenic composition |
| 01/10/2013 | US20130011428 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| 01/10/2013 | US20130011426 Recombinant Vaccines and Use Thereof |
| 01/10/2013 | US20130011425 Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
| 01/10/2013 | US20130011420 Antisense antiviral compounds and methods for treating a filovirus infection |
| 01/10/2013 | US20130011415 Milk derived antigen specific antibodies for inducing an adaptive immune response, methods of preparation and uses thereof |
| 01/10/2013 | US20130011414 Broadly cross-reactive hiv-1-specific antibodies for prevention and treatment of hiv |